NS Pharma, Inc. (United States)
NS Pharma is a biopharmaceutical leader in delivering life-changing care to people living with complex, rare diseases, backed by over 100 years of Nippon Shinyaku development expertise.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
NS Pharma is a biopharmaceutical company focused on advancing revolutionary rare disease therapies. It is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. and serves as an in-house research center of excellence and a commercialization partner to clinical-stage biotechnology companies. The company is developing products for rare diseases such as Duchenne muscular dystrophy, Hunter syndrome, and Eosinophilic granulomatosis with polyangiitis (EGPA).
History
NS Pharma is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. It is a biopharmaceutical leader in delivering life-changing care to people living with complex, rare diseases, backed by over 100 years of Nippon Shinyaku development expertise. The company is advancing revolutionary rare disease therapies that address unmet needs for patients facing debilitating genetic conditions, such as Duchenne muscular dystrophy, Hunter syndrome, and Eosinophilic granulomatosis with polyangiitis (EGPA).
Products and positioning
VILTEPSO (viltolarsen)
An exon-skipping therapy designed for patients with Duchenne muscular dystrophy (DMD), granted accelerated approval by the FDA.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ns-pharma-inc-united-states · Editorial policy · How profiles are compiled